Wed, Jan 28, 2015, 5:41 AM EST - U.S. Markets open in 3 hrs 49 mins

Recent

% | $
Quotes you view appear here for quick access.

Skullcandy, Inc. (SKUL) Message Board

cash2go 92 posts  |  Last Activity: 3 hours ago Member since: Feb 8, 2006
  • Lots of info nobody is talking about. Shouldn't this one be selling at least a buck higher?

  • Reply to

    Wall Street runs from litigation

    by cash2go Oct 31, 2014 11:41 PM
    cash2go cash2go Oct 31, 2014 11:55 PM Flag

    Who is Lane?

    "(U.S. Bankruptcy Judge Sean Lane) said in a ruling yesterday in Manhattan"

  • Reply to

    Wall Street runs from litigation

    by cash2go Oct 31, 2014 11:41 PM
    cash2go cash2go Oct 31, 2014 11:54 PM Flag

    Today's Bloomberg piece:

    " The litigation, pending in Delaware state court, will continue during mediation, and any accord over a possible $232 million in damages reached by the companies will require bankruptcy court approval, Lane said."

  • Dow -vs_Rhome & Hass is a good examples of how markets mis-price an obvious outcome.

    Dow tried to back out of a merger

    Solid contract at $78/share. Rhome and Hass dropped to as low as $57.10. I bought in at cheap price and lived with paranoia of a stock underpriced (or not) maybe because I didn't fully understand corporate law. In a matter of months I got $78/share. It was hard at time to hold because It felt like smarter guys in the know were the reason the stock was at $57.

    Just a matter of time before the speculators moved on and investors gain hold of more and more shares before the final negotiated deal is announced and we have an idea of what the final settlement will look like. Rhom and Hass slowly marched toward $78 as a court date waited. You could still make another $5/share the day the merger was announced on the court steps.

    Dow - vs - Rhome & Hass was a 15 billion merger and followed by the best of analyst and the stock price still allowed for buying heavily discounted shares.

    PharmAthene, a lot of clarity is now out there for anyone to read and get a feel for the value of PIP. I'm accumulating as the vast majority of speculation is now mathematical interpretation vs legal maneuvering . Nolt nearly as speculative to me.

    *LATS terms *84% probability *COGS * 1.4 billion courses at $100 * 13% cost because Parsons said so. * milestone payments * percentage of legal fees reimbursed

    My hope. Siga & Pharmathene are seriously negotiating and will use of tax loss carry forwards...and keep another $100 million or more as profits. A motivated Siga to achieve the most profitable outcome for all is also a new animal that could be very helpful to all in final stage negotiations.

    (reposted, just a reminder that I''m in the paranoid stage with PIP valuation)

  • Reply to

    Siga doing the math

    by cash2go Oct 29, 2014 2:27 AM
    cash2go cash2go Oct 31, 2014 12:38 AM Flag

    T,
    "Revlon officials agreed to pay more than $9.2 million to resolve investors’ claims that Ronald Perelman, the controlling shareholder, shortchanged them in a deal designed to acquire common stock he didn’t already own."

    ("Bad faith" has an ugly definition in Delaware, we should know soon if Siga thinks continuing the lawsuit would only increase the losses)

  • Reply to

    Siga doing the math

    by cash2go Oct 29, 2014 2:27 AM
    cash2go cash2go Oct 29, 2014 10:01 PM Flag

    T,
    Note the wording from the $230M release by Pharmathene:

    SIGA expects it to be substantial - as much as $232 million (or more with post-judgment interest and attorneys' and expert fees) and "SIGA has assumed that any judgment to be entered in this matter will be no less than $180 million (inclusive of pre-judgment interest through the date of entry of judgment by the Court of Chancery as well as professional fees and expenses)."

    Expectations in September 2006 were very high. Parsons and the Supreme Court are in agreement on that. Siga needs to swallow hard and make a deal with Pharmathene. JMHO

  • cash2go by cash2go Oct 29, 2014 12:20 PM Flag

    Portola has entered into Phase 2 and Phase 3 clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer for Eliquis® (apixaban), Bayer HealthCare and Janssen Pharmaceuticals for XARELTO® (rivaroxaban), and Daiichi Sankyo for edoxaban.
    Two ongoing randomized, double-blind, placebo-controlled ANNEXA™ (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) Phase 3 studies are evaluating the safety and efficacy of andexanet alfa in reversing Eliquis- or XARELTO-induced anticoagulation rapidly after an IV bolus and sustaining that effect through a continuous infusion.

    MY WILD GUESS, November is going to be a big month for investors to establish their position in this one for 2015.

  • Reply to

    Siga doing the math

    by cash2go Oct 29, 2014 2:27 AM
    cash2go cash2go Oct 29, 2014 11:50 AM Flag

    COTO report was from May 16, 2011. In 2006 I have no doubt Siga had visions of billions when they went the bad faith path to get rid of Pharmathene agreement.
    However Supremes said lump sum based expectation damages. Does Siga really want to appeal to that same supreme court or negotiate and hope to get a $400M follow on order in the future that would be all theirs?

  • Reply to

    Siga doing the math

    by cash2go Oct 29, 2014 2:27 AM
    cash2go cash2go Oct 29, 2014 11:42 AM Flag

    T
    Doing quick math myself and not using a CPA to do my math.

    84% probability = 16%
    23% = 23& because Parson's said so
    15% COG = 15%

    Equals 54% hit on expectations of $1.4B. That would actually be $476M. Not a CPA so I'm giving it a $300M value when experts do their thing with the total.

    Supreme Court said expectation damages as of 2006.
    BARDA awards $3 billion in vaccine contracts for eradicated smallpox
    ((COTO Report Full Spectrum Defiance))

    In-Pharma Technologist reports, “On May 13 Siga Technologies revealed the US Biomedical Advanced Research and Development Authority (BARDA) had awarded it a five-year, $433m (#$%$306m) contract. However, two days later Siga was forced to suspend work on the contract after Chimerix filed a protest.”
    If all the options in the contract are exercised, it is worth $2.8 billion to Siga, In-Pharma explained.

  • Reply to

    Like a cancer to Motorola

    by see2see Aug 25, 2014 5:28 PM
    cash2go cash2go Oct 29, 2014 10:28 AM Flag

    Think any of these no bid officials will go to jail for costing taxpayers millions. Hope so. Doubt it. Would love to see Relm go after the actual officials and name names in local papers.

  • Reply to

    CROOKS

    by bronx23457 Oct 29, 2014 9:47 AM
    cash2go cash2go Oct 29, 2014 9:52 AM Flag

    It's Wall Street. Nobody pays a personal fine and nobody goes to jail. The guys that know how to set up these kind of scams and pockets their millions know how to protect their personal fortunes.

    Sickening

  • Parson's says do the math with a $1.4 billion contract.

    84% probablility
    23% hit because he said so
    15% COGS

    Why would Siga file Chapter 11?
    The math equals over $300 million, give or take $50M. Siga saying Chapter 11 needed to ensure continued production of Tecovirimat makes sense. Pharmathene negotiating to ensure continued production of Tecovirimat should not be a problem. Pharmathene would also want Siga to work hard at reaching all milestones and use of tax write-offs to recognize the $188M in deferred revenue sitting on their books. Chapter 11 filing confirms a lot of the guesswork on what to expect.

    It's almost November and hearing nothing from Parsons makes me think serious negotiations are progressing between Siga and Pharmathene.

SKUL
10.25-0.04(-0.39%)Jan 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST
Microsoft Corporation
NASDAQTue, Jan 27, 2015 4:00 PM EST
Horizon Pharma plc
NASDAQTue, Jan 27, 2015 4:00 PM EST